Small Molecule Targeted Therapy Market Report 2026

The small molecule targeted therapy market size has grown strongly in recent years. It will grow from $77.29 billion in 2025 to $84.66 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to advances in molecular biology research, increasing prevalence of chronic diseases, expansion of pharmaceutical R&D pipelines, regulatory acceptance of targeted therapies, improved drug screening technologies.

The small molecule targeted therapy market size is expected to see strong growth in the next few years. It will grow to $120.64 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for personalized medicine approaches, rising integration of genomics in drug development, expansion of targeted therapies beyond oncology, growing focus on safety-optimized drug design, increasing investment in precision therapeutics. Major trends in the forecast period include increasing expansion of target-specific drug development, rising use of pathway-modulating therapies, growing adoption of oral small molecule treatments, enhanced focus on disease-specific molecular targets, expansion of combination small molecule regimens.

The increasing focus on personalized medicine is anticipated to drive the growth of the small molecule targeted therapy market in the coming years. Personalized medicine is a healthcare approach that customizes prevention, diagnosis, and treatment based on an individual’s genetic, environmental, and lifestyle factors. The rise of personalized medicine is fueled by advancements in genomics, which provide a deeper understanding of individual genetic variations and enable more precise, targeted treatments that enhance patient outcomes and minimize trial-and-error in therapies. Small molecule targeted therapy supports personalized medicine by specifically targeting a patient’s unique molecular or genetic disease profile, enhancing treatment effectiveness and reducing side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The newly approved personalized treatments in 2023 also include seven cancer drugs and three for other diseases and conditions. As a result, the growing focus on personalized medicine is propelling the growth of the small molecule targeted therapy market.

Major companies operating in the small molecule targeted therapy market are focusing on developing innovative approaches such as oral small molecules to enhance targeted delivery, improve patient adherence, and address specific molecular pathways in oncology and other chronic conditions. Oral small molecule refers to a low-molecular-weight drug administered orally, designed to enter cells efficiently and specifically target disease-associated proteins or pathways. For example, in June 2025, Kura Oncology Inc., a US-based biotechnology company, received FDA approval for a New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory acute myeloid leukemia (AML) with nucleophosmin 1 (NPM1) mutations. This oral targeted therapy is intended for adult patients with relapsed or refractory AML carrying NPM1 mutations, addressing a significant unmet medical need. It demonstrates a favorable safety profile and has shown promising efficacy, including notable complete remission rates in clinical trials. By selectively inhibiting the menin-KMT2A interaction, ziftomenib disrupts leukemic cell proliferation and provides new treatment options for this difficult-to-treat AML subtype.

In May 2025, Eli Lilly and Company, a US-based pharmaceutical firm, acquired SiteOne Therapeutics Inc. for an undisclosed sum. Through this acquisition, Eli Lilly and Company aims to enhance its pain treatment portfolio by creating innovative, non-addictive therapies for chronic pain using advanced sodium channel inhibitors. SiteOne Therapeutics Inc. is a US-based pharmaceutical firm that provides small molecule targeted therapies.

Major companies operating in the small molecule targeted therapy market are F. Hoffmann-La Roche AG (Roche), Merck KGaA, Pfizer Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, Blueprint Medicines Corporation, Kura Oncology Inc., G1 Therapeutics Inc., Ascentage Pharma Group International Inc., Rgenta Therapeutics Inc., Verastem Inc.

North America was the largest region in the small molecule targeted therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the small molecule targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the small molecule targeted therapy market by increasing costs of imported APIs, formulation excipients, analytical instruments, and precision manufacturing equipment. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on international supply chains, while Asia-Pacific faces export-related cost pressures. These tariffs are raising development and production costs and affecting drug pricing dynamics. At the same time, they are promoting regional API production, strengthening domestic pharmaceutical manufacturing, and accelerating supply chain diversification strategies.

The small molecule targeted therapy market research report is one of a series of new reports that provides small molecule targeted therapy market statistics, including small molecule targeted therapy industry global market size, regional shares, competitors with a small molecule targeted therapy market share, detailed small molecule targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule targeted therapy industry. This small molecule targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Small molecule targeted therapy involves low-molecular-weight drugs that directly interact with disease-associated targets like enzymes, receptors, or signaling proteins. They precisely inhibit or regulate disease pathways, enabling targeted treatment while minimizing effects on healthy cells.

The main therapy types of small molecule targeted therapy include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy involves the use of chemical drugs to eliminate rapidly dividing cells in the body. The primary drug classes, such as monoclonal antibodies, small molecule inhibitors, and combination therapies, function through mechanisms including kinase inhibitors, proteasome inhibitors, aromatic hydrocarbon receptor (AHR) modulators, and cell cycle inhibitors. This therapy is used to treat conditions like cancer, autoimmune disorders, and infectious diseases and can be administered orally, intravenously, or subcutaneously.

The small molecule targeted therapy market consists of sales of tyrosine kinase inhibitors, proteasome inhibitors, and BCL-2 inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.